Trials / Conditions / Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

16 registered clinical trials studyying Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Asciminib Roll-over Study NCT04877522	Novartis Pharmaceuticals	Phase 4
Completed	Impact of a Pharmaceutical Care Model in the Management of Chronic Myeloid Leukemia Patients NCT03090477	UCSI University	N/A
Unknown	National Observatory of Chronic Myeloid Leukemia Adolescent and Young Adults Treated With Tyrosine Kinase Inhi NCT02903277	Centre Hospitalier Universitaire de Nice	—
Unknown	Study to Evaluate Tolerability, Safety, Pharmacokinetics and Preliminary Efficacy of PF-114 for Oral Administr NCT02885766	Fusion Pharma LLC	Phase 1 / Phase 2
Unknown	Safety and Efficiency Study of Pioglitazone in Combination With Imatinib Mesylate to Treat Chronic Myelogenous NCT02687425	Meng Li	Phase 2
Withdrawn	Extension Study of IDEAL (Imatinib) for Chronic Myelgenous Leukemia (CML) NCT02421926	Asan Medical Center	—
Completed	Interventional Study to Improve Adherence to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia NCT01768689	pia raanani	N/A
Completed	Effectiveness of Dasatinib in Adult Patients With Chronic Myeloid Leukemia in China: A Multicenter, Registry S NCT02389972	Bristol-Myers Squibb	—
Completed	Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse Aft NCT01774630	University Hospital, Bordeaux	Phase 2
Completed	Pharmacogenomics Validation for Imatinib in Chronic Myeloid Leukemia NCT01437202	Asan Medical Center	—
Completed	Radotinib Versus Imatinib in Newly Diagnosed Philadelphia Chromosome and Chronic Myeloid Leukemia Chronic Phas NCT01511289	Il-Yang Pharm. Co., Ltd.	Phase 3
Unknown	Dasatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia in Japan NCT01464411	Kanto CML Study Group	—
Completed	A Prospective Randomized Phase II Study Evaluating the Monitoring of Imatinib Mesylate Plasmatic Through Level NCT02896842	Versailles Hospital	Phase 2
Completed	Philadelphia Chromosome Positive CML Patients Without Optimal Response or Tolerance to Bcr-Abl TKI NCT01602952	Il-Yang Pharm. Co., Ltd.	Phase 1 / Phase 2
Completed	Treatment of CML Patients With Imatinib and Hydroxyurea (CML2004) NCT02480608	University of Leipzig	Phase 1 / Phase 2
Completed	An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemi NCT00171223	Novartis Pharmaceuticals	Phase 2